Literature DB >> 3447170

Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus.

A T Baker1, J N Varghese, W G Laver, G M Air, P M Colman.   

Abstract

Neuraminidases from different subtypes of influenza virus are characterized by the absence of serological cross-reactivity and an amino acid sequence homology of approximately 50%. The three-dimensional structure of the neuraminidase antigen of subtype N9 from an avian influenza virus (A/tern/Australia/G70c/75) has been determined by X-ray crystallography and shown to be folded similarly to neuraminidase of subtype N2 isolated from a human influenza virus. This result demonstrates that absence of immunological cross-reactivity is no measure of dissimilarity of polypeptide chain folding. Small differences in the way in which the subunits are organized around the molecular fourfold axis are observed. Insertions and deletions with respect to subtype N2 neuraminidase occur in four regions, only one of which is located within the major antigenic determinants around the enzyme active site.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3447170     DOI: 10.1002/prot.340020205

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  32 in total

1.  Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and the trimer of influenza virus hemagglutinin.

Authors:  D C Jackson; B S Crabb; P Poumbourios; W R Tulip; W G Laver
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases.

Authors:  J N Varghese; P M Colman; A van Donkelaar; T J Blick; A Sahasrabudhe; J L McKimm-Breschkin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

3.  Mechanism of antigenic variation in an individual epitope on influenza virus N9 neuraminidase.

Authors:  G M Air; W G Laver; R G Webster
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

4.  Crystallization of biologically active hemagglutinin-neuraminidase glycoprotein dimers proteolytically cleaved from human parainfluenza virus type 1.

Authors:  T Takimoto; W G Laver; K G Murti; A Portner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

5.  Molecular Characterizations of Surface Proteins Hemagglutinin and Neuraminidase from Recent H5Nx Avian Influenza Viruses.

Authors:  Hua Yang; Paul J Carney; Vasiliy P Mishin; Zhu Guo; Jessie C Chang; David E Wentworth; Larisa V Gubareva; James Stevens
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

6.  Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

Authors:  J L McKimm-Breschkin; T J Blick; A Sahasrabudhe; T Tiong; D Marshall; G J Hart; R C Bethell; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

7.  The neuraminidase of bat influenza viruses is not a neuraminidase.

Authors:  Adolfo García-Sastre
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-25       Impact factor: 11.205

8.  The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication.

Authors:  Tracey M Doyle; Bozena Jaentschke; Gary Van Domselaar; Anwar M Hashem; Aaron Farnsworth; Nicole E Forbes; Changgui Li; Junzhi Wang; Runtao He; Earl G Brown; Xuguang Li
Journal:  J Biol Chem       Date:  2013-05-03       Impact factor: 5.157

9.  A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.

Authors:  M T Murrell; M Porotto; O Greengard; N Poltoratskaia; A Moscona
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

10.  Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase.

Authors:  P M Colman; P A Hoyne; M C Lawrence
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.